Cargando…

Predictive biomarkers for tumor immune checkpoint blockade

The development of immune checkpoint inhibitors represented by PD-1 and PD-L1 has provided new hope for the treatment of advanced cancer patients. However, there are no effective predictive biomarkers, which have caused many limitations to the clinical application of immune checkpoint inhibitors. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tong, Mengting, Wang, Jing, He, Wenting, Wang, Yanling, Pan, Hongming, Li, Da, Zhang, Hongliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190817/ https://www.ncbi.nlm.nih.gov/pubmed/30349382 http://dx.doi.org/10.2147/CMAR.S179680

Ejemplares similares

The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer
por: Xu, Yufei, et al.
Publicado: (2022)

Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: a systematic review and meta-analysis of clinical randomized phase III trials
por: Tong, Mengting, et al.
Publicado: (2019)

A Comprehensive Benchmark of Transcriptomic Biomarkers for Immune Checkpoint Blockades
por: Kang, Hongen, et al.
Publicado: (2023)

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
por: Lei, Yanna, et al.
Publicado: (2021)

Research progress of the clinicopathologic features of lung adenosquamous carcinoma
por: Wang, Jing, et al.
Publicado: (2018)

New Prospect for Cancer Cachexia: Medical Cannabinoid
por: Wang, Jing, et al.
Publicado: (2019)

Computational Biology Predicts the Efficacy of Tumor Immune Checkpoint Blockade
por: Kang, Wenyi, et al.
Publicado: (2022)

Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
por: Xiao, Qingyang, et al.
Publicado: (2020)

Medical Cannabinoids for Cancer Cachexia: A Systematic Review and Meta-Analysis
por: Wang, Jing, et al.
Publicado: (2019)

Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
por: Shen, Hongxing, et al.
Publicado: (2019)

Microbial biomarkers for immune checkpoint blockade therapy against cancer
por: Adachi, Keishi, et al.
Publicado: (2018)

Biomarkers for predicting the efficacy of immune checkpoint inhibitors
por: Wang, Chengji, et al.
Publicado: (2022)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

Role of tumor gene mutations in treatment response to immune checkpoint blockades
por: Wang, Manni, et al.
Publicado: (2019)

Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies
por: Yang, Wenwen, et al.
Publicado: (2021)

Immune-Checkpoint Blockade Therapy in Lymphoma
por: Kuzume, Ayumi, et al.
Publicado: (2020)

Neutrophils in the era of immune checkpoint blockade
por: Faget, Julien, et al.
Publicado: (2021)

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma
por: Sarver, Melissa, et al.
Publicado: (2021)

Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies
por: Yang, Richard K., et al.
Publicado: (2020)

Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
por: Peranzoni, Elisa, et al.
Publicado: (2020)

Three Prognostic Biomarkers Correlate with Immune Checkpoint Blockade Response in Bladder Urothelial Carcinoma
por: Guo, Ya, et al.
Publicado: (2022)

Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review
por: Perdikis-Prati, Sarah, et al.
Publicado: (2023)

Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers
por: Wu, Hao-Xiang, et al.
Publicado: (2019)

Immune checkpoint blockades in gynecological cancers: A review of clinical trials
por: Peng, Hongling, et al.
Publicado: (2022)

The Puzzle of Predicting Response to Immune Checkpoint Blockade
por: Onyshchenko, Mykola
Publicado: (2018)

Immune checkpoint blockade in ovarian cancer
por: Weiss, Lukas, et al.
Publicado: (2016)

Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence
por: Huemer, Florian, et al.
Publicado: (2020)

Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer
por: Feng, Mei, et al.
Publicado: (2023)

Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance
por: Park, Young-Jun, et al.
Publicado: (2018)

Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment
por: Arrieta, Víctor A., et al.
Publicado: (2023)

The role of neoantigen in immune checkpoint blockade therapy
por: Yi, Ming, et al.
Publicado: (2018)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
por: Ahn, Brian J., et al.
Publicado: (2013)

Acquired Resistance to Immune Checkpoint Blockade Therapies
por: Zhao, Xianda, et al.
Publicado: (2020)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
por: Wessely, Anja, et al.
Publicado: (2020)

Rethinking immune checkpoint blockade: ‘Beyond the T cell’
por: Liu, Xiuting, et al.
Publicado: (2021)

Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma
por: Lin, Adam Yuh, et al.
Publicado: (2022)

Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy
por: Harber, James, et al.
Publicado: (2021)

Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
por: Zheng, Ming
Publicado: (2022)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020)

Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
por: Lu, Chia-Sing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dk449sui0c8qg765evpqd0hv09